Showing 1 - 10 of 11 Lung Cancers

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >

Status: Enrolling

Investigator: Sindhu Nair

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carbop ... Read more >

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such ... Read more >

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene ... Read more >

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chem ... Read more >

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

Status: Enrolling

Investigator: Chinemerem Abanonu

Study Coordinator:

Phone:

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvemen ... Read more >

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.419.948

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Soli ... Read more >